Iovance Biotherapeutics (IOVA) Total Current Liabilities (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Total Current Liabilities of $129.4 million for Q1 2026, up 5.48% year-over-year from $122.7 million in Q1 2025, and down 6.46% quarter-over-quarter from $138.4 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Total Current Liabilities (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Total Current Liabilities for 17 consecutive years, with $129.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 5.48% year-over-year to $129.4 million; the TTM figure through Mar 2026 stood at $129.4 million (up 5.48% YoY), while the FY2025 annual figure was $138.4 million, up 13.09% from the prior year.
- Total Current Liabilities declined to $129.4 million in Q1 2026 per IOVA's latest filing, from $138.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $138.4 million in Q4 2025 and bottomed at $64.2 million in Q2 2022.
- Historically, Total Current Liabilities has averaged $102.7 million across 5 years, with a median of $91.5 million in 2022.
- Annual changes were most pronounced in 2024 — Total Current Liabilities decreased 4.65% — and 2025, when it surged 47.44%.
- Iovance Biotherapeutics' Total Current Liabilities stood at $91.5 million in 2022, then advanced by 20.57% to $110.3 million in 2023, then advanced by 10.91% to $122.3 million in 2024, then increased by 13.09% to $138.4 million in 2025, then fell by 6.46% to $129.4 million in 2026.
- Business Quant data shows IOVA's Total Current Liabilities at $129.4 million in Q1 2026, $138.4 million in Q4 2025, and $125.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 106.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106.85 Mn |
| Mar 31, 2026 | 129.42 Mn |
| Dec 31, 2025 | 138.36 Mn |
| Sep 30, 2025 | 125.79 Mn |
| Jun 30, 2025 | 129.16 Mn |
| Mar 31, 2025 | 122.69 Mn |
| Dec 31, 2024 | 122.34 Mn |
| Mar 31, 2024 | 83.21 Mn |
| Dec 31, 2023 | 110.31 Mn |
| Sep 30, 2023 | 90.96 Mn |
| Jun 30, 2023 | 88.64 Mn |
| Mar 31, 2023 | 87.27 Mn |
| Dec 31, 2022 | 91.49 Mn |
| Sep 30, 2022 | 79.25 Mn |
| Jun 30, 2022 | 64.19 Mn |
| Mar 31, 2022 | 77.08 Mn |
| Dec 31, 2021 | 89.20 Mn |
| Sep 30, 2021 | 64.77 Mn |
| Jun 30, 2021 | 60.53 Mn |
| Mar 31, 2021 | 55.06 Mn |